India's Pharmaceutical Investment Surges Beyond PLI Targets, Minister Reports
Synopsis
In a remarkable achievement, India's PLI schemes for pharmaceuticals have outstripped investment goals, drawing nearly Rs 42,000 crore and generating significant sales, including substantial exports. This success highlights the growing capabilities of India's pharma sector.
Key Takeaways
India's PLI schemes have attracted Rs 41,943 crore in investments.
Sales generated from these schemes total Rs 3,35,036 crore.
The initiative aims to reduce import dependence in the pharmaceutical sector.
726 APIs, KSMs, and DIs are now being produced under the scheme.
New manufacturing units have been established in Andhra Pradesh.
New Delhi, March 20 (NationPress) The production-linked incentive (PLI) initiatives in India’s pharmaceutical sector have successfully attracted total investments of Rs 41,943 crore across both brownfield and greenfield projects, as reported to Parliament on Friday.
These investments significantly surpass the initially set goal of Rs 17,275 crore over the scheme's six-year duration, Minister of State for Chemicals and Fertilisers, Anupriya Patel, stated in a written response to the Lok Sabha.
The incentive program has generated Rs 3,35,036 crore in sales from 1,988 products, according to the statement from the Ministry of Chemicals and Fertilizers.
This total includes exports worth Rs 2,15,248 crore, and highlights the manufacturing of 726 Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and Drug Intermediates (DIs), with 191 items produced for the first time in India.
The sales of these APIs, KSMs, and DIs have led to cumulative domestic sales amounting to Rs 28,067 crore, thereby aiding in reducing imports within the sector.
Launched in 2021, the PLI scheme for Pharmaceuticals is designed to enhance India’s manufacturing capacity by increasing investments and production in the pharmaceuticals field.
This scheme aims to incentivize the production of high-value medicines, complex generics, and active pharmaceutical ingredients, while the PLI scheme for Bulk Drugs, approved in 2020, focuses on critical KSMs, DIs, and APIs to lessen reliance on single sources.
Under the PLI scheme for Bulk Drugs, Rs 4,814 crore has already been invested in greenfield projects, surpassing the commitment of Rs 4,329.95 crore across six years, the statement added.
Overall, a total capacity of 91,077 metric tonnes per annum is committed for 33 products, exceeding the originally planned capacity of 82,270 metric tonnes per annum for 41 products designated under the scheme.
This initiative has led to the establishment of six new manufacturing units in Visakhapatnam, Andhra Pradesh, categorized as an aspirational district.
aar/na
Point of View
The significant surpassing of investment targets by India's PLI schemes reflects a robust commitment to enhancing the country's pharmaceutical manufacturing capabilities. This achievement not only bolsters the economy but also positions India as a key player in the global pharmaceuticals market.
NationPress
10 May 2026
Frequently Asked Questions
What are the PLI schemes for pharmaceuticals?
The PLI schemes for pharmaceuticals are government initiatives designed to boost investment and production in the pharmaceutical sector, encouraging the manufacturing of high-value medicines and active pharmaceutical ingredients.
How much investment has the PLI scheme attracted?
The PLI scheme has attracted cumulative investments of approximately Rs 41,943 crore across various projects.
What is the purpose of the PLI scheme?
The purpose of the PLI scheme is to enhance India's manufacturing capabilities, reduce import reliance, and promote the production of critical pharmaceutical products.
What products are included under the PLI scheme?
The scheme includes a variety of products such as Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and complex generics.
Where have new manufacturing units been established?
New manufacturing units have been set up in Visakhapatnam, Andhra Pradesh, as part of this initiative.
